SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
INTRODUCTION The SWI/SNF (SWitch/Sucrose Non-Fermentable) chromatin remodeling complex acts as a regulatory component of transcription, and inactivating mutations within the complex are implicated in genomic instability, higher tumor mutational burden (TMB), and an aggressive cancer phenotype. Whether SMARCA4 and other SWI/SNF alterations are independent prognostic factors or associated with clinical outcomes to immune checkpoint inhibitors (ICIs) in NSCLC remains unclear. METHODS We collected clinicopathologic and genomic data from patients with NSCLC that underwent targeted next-generation sequencing (NGS) at the Dana-Farber Cancer Institute. Tumors were characterized based on the presence or absence of mutations across a set of 6 SWI/SNF genes (ARID1A, ARID1B, ARID2, PBRM1, SMARCA4, and SMARCB1). RESULTS Of 2689 patients with NSCLC, 20.6% (N=555) had SWI/SNF genomic alterations. Compared to SWI/SNF wild-type (wt) NSCLC, patients with SWI/SNF mutant NSCLCs had a lower prevalence of concurrent targetable driver mutations (33.2% vs 22.2%; P<0.001), a higher TMB (median 8.5 vs 12.2 mutations/megabase; P<0.001), a shorter median overall survival (mOS) from the time of advanced disease diagnosis (25.0 vs 19.3 months; P=0.01); the detrimental effect in OS appeared to be largely driven by SMARCA4 mutations (mOS: 25.0 months for SMARCA4 wt vs 15.6 months for SMARCA4 mutant; P<0.001). Among 532 patients who received ICIs, 25.5% (N=136) harbored SWI/SNF mutations. From the start of immunotherapy, there was no difference in objective response rate (ORR 19.9% vs 25.0%; P=0.2), median progression-free survival (mPFS 3.0 vs 3.0 months; HR: 0.96 [95% CI: 0.77-1.18]; P=0.7), or mOS (13.1 vs 9.5 months; HR: 0.81 [95% CI: 0.64-1.02]; P=0.07) in SWI/SNF wt vs SWI/SNF mutant NSCLC, respectively. However, among KRAS-mutant NSCLCs treated with ICIs (N=176), a concurrent SWI/SNF mutation (N=39) conferred a numerically lower ORR (21.9% vs 12.8%; P=0.2), a significantly shorter mPFS (4.1 vs 1.8 months; HR: 0.57 [95%CI: 0.38-0.84]; P=0.005), and a significantly shorter mOS (15.5 vs 8.2 months; HR: 0.56 [95%CI: 0.36-0.86]; P=0.008). The deleterious effect on immunotherapy outcomes in KRAS-mutant NSCLC was most pronounced in the SMARCA4-mutant subset (N=17), with a lower ORR (22% vs 0%, P=0.03) a significantly shorter mPFS (4.1 vs 1.4 months; HR: 0.25 [95%CI: 0.14-0.42]; P<0.001), and a significantly shorter mOS (15.1 vs 3.0 months; HR: 0.29 [95%CI: 0.17-0.50]; P<0.001) compared to SMARCA4-wt KRAS-mutant NSCLCs. CONCLUSIONS Although there were no significant associations between SWI/SNF mutation status and immunotherapy efficacy in the overall NSCLC cohort, the presence of a SMARCA4 alteration may confer a worse outcome to immunotherapy among KRAS-mutant NSCLCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194
The mutational constraint spectrum quantified from variation in 141,456 humans
Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J., Wang, Q., Collins, R. L., Laricchia, K. M., Ganna, A., Birnbaum, D. P., et al. (2020) · Nature · doi:10.1038/s41586-020-2308-7 · Cited by 9,434
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
COSMIC: somatic cancer genetics at high-resolution
Forbes, S. A., Beare, D., Boutselakis, H., Bamford, S., Bindal, N., Tate, J., Cole, C. G., Ward, S., Dawson, E., Ponting, L., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1121 · Cited by 1,922
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789
The mutational constraint spectrum quantified from variation in 141,456 humans
Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J., Wang, Q., Collins, R. L., Laricchia, K. M., Ganna, A., Birnbaum, D. P., et al. (2019) · doi:10.1101/531210 · Cited by 1,662
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641
Self-citationRizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3384 · Cited by 1,367
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bossé, D., Wankowicz, S. M., Cullen, D., et al. (2018) · Science · doi:10.1126/science.aan5951 · Cited by 1,249
Cited by
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Negrao, M. V., Araujo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M., Minuti, G., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1420 · Cited by 203
Self-citationAlessi, J. V., Elkrief, A., Ricciuti, B., Wang, X., Cortellini, A., Vaz, V. R., Lamberti, G., Frias, R. L., Venkatraman, D., Fulgenzi, C. A. M., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.01.091 · Cited by 97
Self-citationClinicopathologic characteristics and outcomes for patients with KRAS G12D-mutant NSCLC
Cooper, A. J., Muzikansky, A., Lennerz, J., Narinesingh, F., Mino-Kenudson, M., Hung, Y. P., Piotrowska, Z., Dagogo-Jack, I., Sequist, L. V., Gainor, J. F., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100390 · Cited by 14
Metadata
- Authors
- Alessi, J. V., Ricciuti, B., Spurr, L. F., Gupta, H., Li, Y. Y., Glass, C., Nishino, M., Cherniack, A. D., Lindsay, J., Sharma, B., Felt, K. D., Rodig, S. J., Cheng, M. L., Sholl, L. M., & Awad, M. M.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 16
- Issue
- 7
- Pages
- 1176-1187
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W3153869942
- Cited by
- 155
- References
- 17
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.